COVID-19 and coinfection with *Clostridioides (Clostridium) difficile* in an infant with gastrointestinal manifestation

COVID-19 e coinfecção por *Clostridioides (Clostridium) difficile* em lactente com manifestações gastrintestinais

Jane Oba¹, Clovis Artur Silva², Ricardo Katsuya Tomá³, Werther Brunow de Carvalho², Artur Figueiredo Delgado²

¹ Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
² Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

DOI: 10.31744/einstein_journal/2020RC6048

**ABSTRACT**

We report the clinical case of an infant with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with gastrointestinal signs and symptoms, predominantly vomiting. The patient also had colic, poor feeding, mild diarrhea and mild rhinorrhea without fever. The child had evidence of altered coagulation, increased interleukin 10, moderate dehydration and she was admitted to the pediatric intensive care unit. Simultaneously, the patient was diagnosed as *Clostridioides difficile* infection, which possibly may have facilitated the persistence of SARS-CoV-2 in feces, for more than 27 days, even after the nasopharyngeal test turned negative. This coinfection might exacerbate the gastrointestinal signs and symptoms and increased the possibility of fecal-oral transmission of SARS-CoV-2 and *Clostridioides*. The patient was breastfed and received complementary infant formula, hydrated with intravenous fluid, and was discharged without complications, 4 days after admission.

**Keywords**: COVID-19; Coronavirus infections; Coinfection; Clostridium; Gastrointestinal tract; Infant

**RESUMO**

Relatamos o caso clínico de uma lactente com infecção por coronavírus da síndrome respiratória aguda grave 2 (SARS-CoV-2) com sinais e sintomas gastrintestinais – predominantemente vômites. A paciente apresentou, adicionalmente, cólica, dificuldade para mamar, evacuações amolecidas e rinorrea leve, sem febre. Houve evidências de alterações da coagulação, aumento de interleucina 10 e desidratação moderada, que justificaram internação na unidade de terapia intensiva. Simultaneamente, a paciente foi diagnosticada com infecção por *Clostridioides difficile*, que pode ter facilitado a persistência do SARS-CoV-2 nas fezes por mais de 27 dias, mesmo após negativação do teste nasofaríngeo. Essa coinfecção pode ter exacerbado os sinais e sintomas gastrintestinais e aumentado a possibilidade da transmissão do SARS-CoV-2 e *Clostridioides*. A paciente foi mantida em aleitamento materno e complemento com fórmula infantil, recebeu hidratação intravenosa e teve alta hospitalar, sem complicações, após 4 dias de internação.

**Descritores**: COVID-19; Infecções por coronavírus; Coinfecção; Clostridium; Trato gastrointestinal; Lactente

**INTRODUCTION**

The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) rapidly spread as a global...
pandemic. Emerging data regarding the clinical characteristics of infected children from China, Europe and the United States have shown that almost 20% of infection occurred in infants (less than 12 months), and the severity of illness is higher compared with older children. In addition, the potential harm of COVID-19 in infants and its prognosis remain unknown. The infection in infants have distinct clinical/radiologic characteristics from adults, and accounts for 48% of hospitalizations of all infected children and adolescents. Reported clinical manifestations among infants with SARS-CoV-2 infection are predominantly respiratory, such as fever, cough, rhinorrhea, increased work of breathing and lethargy. Moreover, almost 25% of cases also include gastrointestinal (GI) events, like vomiting, diarrhea, abdominal pain, feeding intolerance or decreased intake.

Nearly 50% of infected children with SARS-CoV-2 were also coinfected with respiratory pathogens. Attention now is given to the GI tract, since recent evidence has suggested that SARS-CoV-2 can actively colonize and replicate in the GI tract. These findings have important implications for disease transmission and management, and the occurrence of enteropathogenic coinfection, particularly Clostridioides difficile (CD), formerly known as Clostridium difficile.

Infants colonized with toxigenic C. difficile rarely develop clinical disease, and the reasons are unknown. There are substantial gaps in the available data regarding COVID-19 in infants and coinfection with C. difficile. We describe a case report of an infant with COVID-19 coinfected with C. difficile. To the best of our knowledge, there are no reports about this kind of enteropathogenic coinfection in neonates and infants.

CASE REPORT

A 2-month-old female infant previously healthy, presented to the pediatric emergency department. The infant’s mother reported weight loss, colic, crying for feeding alternating with lethargy, mild diarrhea and worsening of vomiting beginning 5 days before. Previously, she reported nasal congestion, sporadic cough, conjunctivitis, small skin vesicles on the chest and no fever. The real time reverse transcription-polymerase chain reaction (RT-PCR) SARS-CoV-2 nasopharyngeal test result was positive (Table 1).

![Figure 1. Chronology of clinical, laboratory and imaging events](image-url)
The mother had been infected with SARS-CoV-2 10 days before the child. On physical examination, the infant was markedly irritable alternating with lethargy, with painful facies suggestive of abdominal colic associated to interruption of feeding several times, moderate dehydration, and hypothermia (<36°C). Her weight was 4.8kg, she had a mottled skin, prolonged capillary refill and a decreased urine output. Pulse rate was 125 beats/minute, respiratory rate was 54 breaths/minute, and oxygen saturation by pulse oximetry of 97% in room air.

During 4 days of hospitalization in the PICU, the patient persisted with abdominal colic, and required additional intravenous fluids due poor acceptance of breast milk or infant formula. The proton pump inhibitor initially prescribed was withdrawn. The patient was not prescribed antivirals, glycoocorticoids or antimicrobials.

### Table 1. Laboratory and imaging results during the clinical course

| Variables                  | Hospital admission | Day 10 | Day 27 |
|----------------------------|--------------------|--------|--------|
| SARS-CoV2                  | Oral swab: positive Stool: positive | Oral swab: negative Stool: positive |
| Hemoglobin, g/dL           | 11.4              | 9.6    | 10.5   |
| Hematocrit, %              | 31.9              | 27.7   | 30.5   |
| White blood cell count, μL | 12,460            | 9,940  | 7,970  |
| Neutrophils, μL (1000-8500)| 623               | 2,565  | 1,363  |
| Lymphocyte, μL (4000-13500)| 9,843             | 6,706  | 6,481  |
| Platelets, ×10^3/μL (150-450)| 470              | 503    | 427    |
| CRP, mg/L (<5.0)           | <1                | 0.3    | <0.3   |
| Albumin, g/dL (3.1-5)      | 4.1               |        |        |
| Ferritin, ng/mL (8.46-680)| 503               | 388    |        |
| AST, U/L (<25)             | 70                | 36     |        |
| ALT, U/L (<25)             | 42                | 18     |        |
| Urea, mg/dL (4.16)         | 8                 |        |        |
| Creatinine, mg/dL          | 0.30              |        |        |
| Prothrombin time, (16-26.1)| 29.6              | 27.9   |        |
| Fibrinogen, mg/dL (200-400)| 177               | 161    |        |
| TTPa, (25.6-35.6)          | 33.5              |        |        |
| D-dimer, ug/mL (<500)     | 641               | 751    |        |
| Troponin, pg/mL (<5)      | 11                | 22     | 16     |
| IL-6, pg/mL (1.5-7.0)    | 2.2               |        |        |
| IL-10, pg/mL (0-2)        | 2.3               |        |        |
| Hemoculture               | Negative          |        |        |
| Clostridioides difficile in stool | Positive          | Positive | Positive |
| Echocardiography          | Normal            | Normal |        |
| Transfontanellar brain ultrasonography | Normal |          |
| Abdominal ultrasonography | Normal            |        |        |

The clinical reports of COVID-19 in infants reveal that GI symptoms might be the sole clinical presentation of the disease, more prominent than respiratory symptoms, like the patient described.⁴,⁵ It is important to highlight that COVID-19 in infants can be a severe illness compared with older children due to immaturity of the immune system. Consequently infants are potentially at risk for more significant complications and might require ICU support.⁴,⁵

Co-infections with others respiratory pathogens than SARS-CoV-2 are common, but with enteropathogens, particularly with *C. difficile*, have not been reported yet in infants. The clinical spectrum of *C. difficile* disease ranges from self-limiting secretory diarrhea to pseudomembranous colitis and septic shock. Two important features of *C. difficile* in infants are the highest incidence in the first year of life (14% to 37%) and frequent colonization with no clinically relevant symptoms.⁶ Polymerase chain reaction assay *C. difficile* detects the regulatory gene (tdcC) responsible for production of toxins A and B, with no detection of toxin, and the results often reflect *C. difficile* colonization rather than disease. For reasons that remain undefined, the colonized infants show no toxigenic effects from exotoxins released by *C. difficile*, in contrast to older children and adults who are susceptible to severe diarrhea and colitis. It has been proposed that the immature intestinal mucosa might lack receptors for *C. difficile* toxin.⁶

Other important factor is the protective
properties of breastmilk, since breastfed infants have lower rates of *C. difficile* colonization (14%) compared to formula-fed infants (30%). In this case, damage to the gut due to SARS-CoV-2 might facilitate the coinfection with *C. difficile*; and despite the protective factors of breast milk and the infant immunity, these were not enough to cease the elimination of the virus by feces. Additionally, the acid-suppression with proton pump inhibitor might facilitate the infection with *C. difficile.*

The patient’s laboratory findings showed minor changes in white blood cell counts and the inflammatory markers, C-reactive protein and ferritin were normal (Table 1), as reported by other similar study. Nevertheless, more specific biomarkers, such as altered coagulation screen, thrombocytosis, increased IL-10 serum concentration and D-dimer suggested any degree of a systemic inflammatory disease. The Doppler echocardiography and chest CT of patient were normal. The importance of CT to diagnose COVID-19 in children is debated by some authors, because one-half of the cases did not show any radiologic changes during course of the disease.

The patient was not prescribed antivirals, glycoscorticoids, or antimicrobial agents considering the efficacy of these drugs is uncertain. We encouraged breastfeeding because it is considered protective for SARS-CoV-2 and *C. difficile*, and is an unlikely source of infection transmission. In addition, there is insufficient data to demonstrate efficacy of probiotics in treating *C. difficile* infection.

In agreement with other authors, the stool test remained positive for SARS-CoV-2 1 month after diagnosis, suggesting the possibility of prolonged fecal-oral transmission.

**CONCLUSION**

This case shows the long-term impact of COVID-19 on infant’s health is still unknown. Many uncertainties persist regarding the infection by SARS-CoV-2 in infants, mainly when coinfected by other enteropathogens. More robust data and studies with a larger sample of infants are warranted to clarify the determinants of gastrointestinal infection presentation and severity. Breastfeeding seems to be a protection factor and may be continued in mothers with SARS-CoV-2.

**ACKNOWLEDGMENTS**

We acknowledge Dra. Mariana Rodrigues and Dr. Márcio Caldeira Alves Moreira for assistance support.

**REFERENCES**

1. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702.
2. Götzinger F, Santiago-Garcia B, Noguera-Julian A, Lasnspa M, Lancellia L, Calo Carducci F, Gabrovskia N, Velizarova S, Prunk P, Osterman V, Krivec U, Lo Vecchio A, Shingadia D, Soriaño-Arandes A, Melendo S, Lanari M, Piaertoni L, Wagner N, L’Huillier AG, Heininger U, Ritzi N, Bandi S, Krajcar N, Roglic S, Santos M, Christaens C, Creuen M, Buonsenso D, Welch SB, Bogyi M, Brinkmann F, Tebuegege M; ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653-61.
3. Feld L, Belfer J, Kabra R, Goenka P, Rai S, Moriarty S, et al. A case series of the 2019 novel coronavirus (SARS-CoV-2) in 3 febrile infants in New York. Pediatrics. 2020;146(1):e20201056.
4. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and other clinical characteristics of COVID-19 in children. Pediatrics. 2020;146(1):e20200961.
5. Oba J, Carvalho WB, Silva CA, Delgado AF. Gastrointestinal manifestations and nutritional therapy during COVID-19 pandemic: a practical guide for pediatricians. einstein (São Paulo). 2020;18:eRW5774. Review. http://dx.doi.org/10.31744/einstein_journal/2020RW5774
6. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):943-51. Review.
7. Schutze GE, Willoughby RE; Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics. 2013;131(1):196-200. Review.
8. McLaren SH, Dayan PS, Fenster DB, Ochs JB, Vindas MT, Bugaighis MN, et al. Novel coronavirus infection in febrile infants aged 60 days and younger. Pediatrics. 2020; 146(3):e20201550.
9. Borali E, De Giacomo C. Clostridium difficile infection in children: a review. J Pediatr Gastroenterol Nutr. 2016;63(6):e130-40. Review.
10. Hong H, Wang Y, Chung HT, Chen CJ. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. Pediatr Neonatol. 2020;61(2):131-2.